Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT01505192 |
| Other study ID # |
Postpartum non invasive Hb |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
N/A
|
| First received |
December 28, 2011 |
| Last updated |
January 5, 2012 |
| Start date |
December 2011 |
| Est. completion date |
May 2012 |
Study information
| Verified date |
January 2012 |
| Source |
Città di Roma Hospital |
| Contact |
Giorgio Capogna, MD |
| Email |
capogna.giorgio[@]gmail.com |
| Is FDA regulated |
No |
| Health authority |
Italy: Ministry of Health |
| Study type |
Interventional
|
Clinical Trial Summary
Aim of this study is to determine the physiological reference individual values (RI) of
maternal continuous SpHb immediately after delivery in the post-partum period (continuous
monitoring up to 2 hours after delivery) in order to establish the physiological Hb
variations in response to the physiological blood loss due to delivery.
During labor all parturients will be tested for standard Laboratory Hb and monitored for at
least 30 minutes with SpHb monitoring equipment (Radical-7™ Pulse CO-Oximeter and Rainbow
DiSposable™ Adult Adhesive Sensor), and these values will be considered to be the baseline
values.
Immediately after spontaneous vaginal delivery, venous blood sample will be taken for Hb
determination and Radical 7 equipment for SpHb will be connected to the patient's finger and
will be recorded for at least two hours after delivery. At the end of this period of
observation a venous blood sample will be taken for Hb determination. Additional
measurements of both SpHb and Lab Hb will be performed 24 hours after delivery.
Description:
Background and Significance:
Pregnancy and childbirth involve health risks, even for women without any pre-existing
health problems. Postpartum hemorrhage is one of most common complications for delivering
mothers and causes 19% of in-hospital maternal deaths (Bateman BT et al. "The Epidemiology
of Postpartum Hemorrhage in a Large, Nationwide Sample of Deliveries" Anesthesia and
Analgesia 2010 110:1368-1373) . Due to pregnancy physiological changes, maternal bleeding is
typically discovered after a significant change in vital signs, and/or symptoms, and usually
confirmed with an invasive laboratory hemoglobin test. This can result in late detection of
bleeding that can affect patient outcome. Early detection of signs and symptoms of obstetric
hemorrhage is therefore crucial. Non-invasive and continuous hemoglobin (SpHb) monitoring
system quickly measures current hemoglobin levels and continuously tracks them in real-time
to detect falling hemoglobin levels that may, in turn, represent an early sign of a
potential hemorrhage. Unfortunately there is no validation of the clinical accuracy of the
Rainbow device for the noninvasive and continuous hemoglobin (SpHb) monitoring in the
obstetric setting nor any information concerning its use as a tool for the early detection
of postpartum hemorrhage.
The investigators therefore propose to undertake an open, preliminary, sequential pilot
study to determine the physiological values (RI) of maternal continuous SpHb in the
post-partum period.
Study Objective:
To determine the physiological reference individual values (RI) of maternal continuous SpHb
immediately after delivery in the post-partum period (continuous monitoring up to 2 hours
after delivery) in order to establish the physiological Hb variations in response to the
physiological blood loss due to delivery.
Inclusion and exclusion criteria
Healthy parturients in labor will be asked to be enrolled in the study and informed consent
will be obtained.Parturients will be consecutively included in this study. Bleeding risk
subjects will be excluded (parturients who had:
Operative or instrumental vaginal delivery,Estimated blood loss greater than 500 mL, who had
II and III degree perineal lacerations, any coagulation disorder or anticoagulant therapy)
Sample Size Since we have no available information on the expected distribution of the
outcome, we will use a sequential design. The main endpoint of our analysis will be a
reliable estimate for the outcome expected in healthy women after labor.
The investigators will state their target estimate as being reliable when the ratio between
the estimate and its standard error is smaller than 2.
The International Federation of Clinical Chemistry (IFCC) and Clinical Laboratory and
Standards Institute (CLSI) guidelines in 2008 recommended to establish RIs with at least 120
reference individuals using the nonparametric ranking method (Clinical and Laboratory
Standards Institute. Defining, Establishing, and Verifying Reference Intervals in the
Clinical Laboratory; Approved Guideline. 3rd ed. Wayne, PA: CLSI; 2008) and thus we will
include in the study a sample of at least 120.
Methods During labor all parturients will be tested for standard Laboratory Hb and monitored
for at least 30 minutes with SpHb monitoring equipment (Radical-7™ Pulse CO-Oximeter and
Rainbow DiSposable™ Adult Adhesive Sensor), and these values will be considered to be the
baseline values.
Immediately after spontaneous vaginal delivery, venous blood sample will be taken for Hb
determination and Radical 7 equipment for SpHb will be connected to the patient's finger and
will be recorded for at least two hours after delivery. At the end of this period of
observation a venous blood sample will be taken for Hb determination. Additional
measurements of both SpHb and Lab Hb will be performed 24 hours after delivery.
According to the SpHB data collection-research protocol, sensor site will be connected to
the patient's ring finger of the non-dominant hand. Sensor handling and placement will also
follow the instructions of the SpHB data collection-research protocol.
Sensor will be attached to the same arm as the blood draw. Sensor placement on the hand of
the side with the blood pressure cuff will be avoided unless they are drawing blood from
that extremity. Placing the sensor and drawing blood from the same arm that is being used
for IV infusions will be also avoided.
SpHb results will be not included when the Perfusion Index (PI, noninvasive index of
peripheral perfusion and vasomotor tone) values will be less than 0.5.
Concerning blood sampling, blood will be drawn directly into the vacutainer by using a
needle no smaller than 20G and analyzed within 15 min of the blood draw.
In Vivo adjustment and Trend Accuracy
SpHb accuracy with an in vivo adjustment will be calculated by using the new Radical 7
equipment with in vivo adjustment feature software which will take the bias between the
first SpHb and first laboratory tHb measurement and will adjust all subsequent measurements
for that case.
The trend accuracy will be calculated by using the following time points: pre-delivery, 2
hrs after delivery and 24 hr after delivery.
Calibrated SpHb measurements will be compared to subsequent laboratory values to create a
Bland Altman plot and calculate bias, and confidence interval.
